NCT05130515

Who might be able to join this trial:

• You understood what the study involves, agreed to take part, and signed a consent form.
• You are a woman between 18 and 70 years old.
• Your cancer has been confirmed by a tissue test (biopsy) to be ovarian clear cell carcinoma (a specific type of ovarian cancer).
• Your cancer came back or got worse during platinum-based chemotherapy after surgery, OR came back or got worse within 6 months of finishing at least 4 rounds of platinum-based chemotherapy.
• Doctors expect you to live for more than 16 weeks.
• You are generally able to carry out daily activities with little or no limitation (confirm with trial site for exact definition).
• Your blood counts, kidney function, and liver function are within acceptable ranges as measured by blood tests.
• You have tested negative for pregnancy and are willing to use reliable contraception during the trial and for 3 months after your last dose, or you abstain from sex, or you are not able to become pregnant.
• You are able to follow the study schedule and requirements.
• Any side effects from previous chemotherapy have mostly cleared up before joining (minor nerve tingling or hair loss up to a moderate level may still be acceptable).
• You have at least one measurable area of cancer that can be tracked on scans.
• It has been at least 4 weeks since your last cancer treatment (or at least 6 weeks if your previous chemotherapy included a drug called mitomycin).

Who may not be able to join:

• You have previously been treated with a type of drug called a PARP inhibitor.
• You are allergic to niraparib or any of its ingredients, or to similar medicines.
• You are allergic to anlotinib or any of its ingredients, or to similar medicines.
• You have active, uncontrolled cancer that has spread to your brain or the lining around your brain (some exceptions may apply — confirm with trial site).
• You had major surgery within the 3 weeks before joining, or you have not fully recovered from surgery.
• You received radiotherapy to more than 20% of your bone marrow within the week before joining.
• You have been diagnosed with another type of cancer within the past 2 years (except for certain fully treated skin cancers).
• You have a specific type of lung cancer involving the central airways, or you are at high risk of coughing up large amounts of blood.
• You have been diagnosed with certain blood or bone marrow disorders (such as MDS or AML — confirm with trial site).
• You have serious or uncontrolled health conditions, such as uncontrolled nausea or vomiting, active HIV, hepatitis B or C, uncontrolled seizures, or a weakened immune system.
• You have had significant bleeding events in the past 3 to 6 months, a history of gastrointestinal bleeding, active bleeding, or you are taking blood-thinning medications such as warfarin, heparin, aspirin (long-term), or clopidogrel.
• You have had a stroke, mini-stroke (TIA), or blood clot in the lungs within the past 6 months.
• You have serious heart problems, such as severe heart failure, a recent heart attack, unstable chest pain, uncontrolled high blood pressure (above 150/100 mmHg), significant heart valve disease, or certain heart rhythm problems.
• You have very low sodium or potassium levels in your blood, or a thyroid condition that cannot be controlled with medication.
• You have received a platelet or red blood cell transfusion within 4 weeks before starting the study drug.
• You are pregnant, breastfeeding, or planning to become pregnant during the trial.
• You have a specific abnormality on your heart tracing (ECG) called a prolonged QTc interval above 450 ms (confirm with trial site if you have a pacemaker).
• You have any other condition, treatment history, or test result that the study doctor believes would make participation unsafe or unsuitable for you.

Important: Always verify eligibility with the trial site directly before applying.